These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11758069)

  • 1. Are the new Lipid Management Guidelines good for Australia's health?
    Jackson RT
    Med J Aust; 2001 Nov; 175(9):452-3. PubMed ID: 11758069
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversies in dyslipidaemia management.
    Stock J
    Atherosclerosis; 2012 Apr; 221(2):321-4. PubMed ID: 22305261
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 5. Application in general practice of treatment guidelines for patients with dyslipidaemia: the RESPECT study.
    Cacoub P; Tocque-Le Gousse E; Fabry C; Hermant S; Petzold L
    Arch Cardiovasc Dis; 2008; 101(11-12):715-21. PubMed ID: 19059566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 8. Implementing new guidelines in the management of blood cholesterol.
    Boyden TF; Brook RD; Jackson E; Rubenfire M; Eagle K
    Am J Med; 2014 Aug; 127(8):705-6. PubMed ID: 24569024
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
    Forge BH; Briganti EM
    Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin therapy: when to think twice.
    Wahawisan J; Tovar JM; Granberry MC
    J Fam Pract; 2013 Dec; 62(12):726-32. PubMed ID: 24340334
    [No Abstract]   [Full Text] [Related]  

  • 12. [Limitations of interventions against hypercholesterolemia].
    Ripoll MA
    Aten Primaria; 1996 Mar; 17(4):305-6. PubMed ID: 8679872
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
    Kazi DS; Penko J; Ollendorf DA; Coxson PG; Bibbins-Domingo K
    Ann Intern Med; 2018 Jun; 168(12):896-898. PubMed ID: 29610832
    [No Abstract]   [Full Text] [Related]  

  • 14. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 15. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 16. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 17. 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.
    Volpe M; Volpe R; Gallo G; Presta V; Tocci G; Folco E; Peracino A; Tremoli E; Trimarco B;
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):313-329. PubMed ID: 28523635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)].
    Wiersma T; Smulders YM; Stehouwer CD; Konings KT; Lanphen J
    Ned Tijdschr Geneeskd; 2012; 156(36):A5104. PubMed ID: 22951134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UK review finds statins are cost effective in secondary prevention.
    Kmietowicz Z
    BMJ; 1999 Nov; 319(7222):1390. PubMed ID: 10574845
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG
    Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.